Pfizer biosimilar to Roche Herceptin wins USFDA nod
The approval for Pfizer comes nearly a year after the agency declined to approve the drug, Trazimera, and sought additional technical information. The USFDA had declined to approve Pfizer’s biosimilar of Herceptin in April.
New Delhi: The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.
The approval for Pfizer comes nearly a year after the agency declined to approve the drug, Trazimera, and sought additional technical information. The USFDA had declined to approve Pfizer’s biosimilar of Herceptin in April.
Since then, the FDA has approved a biosimilar to Herceptin from Celltrion Inc, and one developed by Samsung Bioepis Co Ltd, a joint venture between Samsung Biologics and Biogen Inc.
Medical Dialogues had earlier reported that USFDA had approved a biosimilar to Roche Holding AG’s blockbuster breast cancer treatment, Herceptin. The biosimilar, Ontruzant, is sold by Merck Sharp & Dohme Corp, a unit of Merck & Co Inc, and is developed by Samsung Bioepis Co Ltd, which is a joint venture between Samsung BioLogics and Biogen Inc.
Also Read: Samsung Bioepis biosimilar to Roche Herceptin wins FDA nod
The FDA has also approved Mylan's biosimilar of Herceptin.
Herceptin is one of Roche's top drugs and brought in sales of 6.98 billion Swiss francs in 2018. Herceptin is one of the world’s most successful antibody drugs and has been a mainstay of Roche profits for many years. However, sales have been hit by rising competition from cheaper biosimilars, particularly in Europe.
Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision. Their similar versions are called biosimilars, instead of generics.
Pfizer is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.
Also Read: No selection process-ICMR, Pfizer collaboration on AMR project draws Objections from industry
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd